Inhibrx Biosciences reports positive Ph2 trial data, stock gains
Investing.com Gold reports: Inhibrx Biosciences reports positive Ph2 trial data, stock gains. Full body text was unavailable at ingest time, so this brief is based on headline context.
Investing.com Gold reports: Inhibrx Biosciences reports positive Ph2 trial data, stock gains. Full body text was unavailable at ingest time, so this brief is based on headline context.